• PDF / 169,726 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 58 Downloads / 184 Views

DOWNLOAD

REPORT

---

1

Human-papillomavirus-vaccine-recombinant-bivalent-Japan-Vaccine/Medimmune

S

Postural orthostatic tachycardia syndrome: case report An 18-year-old woman developed postural tachycardia syndrome (POTS) following treatment with human papillomavirus vaccine recombinant bivalent japan vaccine/medimmune [Cervarix; route and dosage not stated]. The woman received human papillomavirus vaccine recombinant bivalent japan vaccine/medimmune. However, her autonomic function tests revealed postural tachycardia on a tilt table test. Her breathing, Valsalva, skin biopsy and quantitative sudomotor axon reflex test (QSART) were normal. The examination of cerebrospinal fluid did not show any evidence of infection, inflammation or demyelination. Further analysis of systemic and neurologic autoimmune disorders was negative. Her serum showed the presence of functionally active anti-beta-2 adrenergic (b2-AAB) and anti-muscarinic receptor-2 antibodies (M2-AAB), using bioassay (Berlin Cures GmbH). She was bedridden with dizziness, postural tachycardia, nausea, cognitive dysfunction and extreme fatigue for five years, even after receiving various unspecified medications and non-pharmacotherapy for POTS. Later, the woman was treated with plasmapheresis, IV immune-globulin and prednisolone. Subsequently, her condition improved. The symptoms re-occurred after immunotherapy was held and and resolved with the reinstitution of immunotherapy. Del Pozzi AT, et al. Immunotherapy as an effective treatment of POTS with functionally active adrenergic and muscarinic antibodies after human papillomavirus vaccination: 803503328 A case report. Clinical Autonomic Research 29: 527, No. 5, Jan 2019. Available from: URL: http://doi.org/10.1007/s10286-019-00631-x [abstract]

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823